Background: Regorafenib is a small molecule multikinase inhibitor that inhibits multiple kinases including BRAF, KIT, PDGFRB, RAF, RET, and VEGFR1-3.
Procedures: The in vivo anticancer effects of regorafenib were assessed in a panel of six osteosarcoma models, three rhabdomyosarcoma models, and one Ewing sarcoma model.
Results: Regorafenib induced modest inhibition of tumor growth in the models evaluated.
Conclusion: The overall pattern of response to regorafenib appears similar to that of the kinase inhibitor sorafenib, with pronounced slowing of tumor growth in some models, limited to the period of agent administration, being the primary treatment effect.
Keywords: Ewing sarcoma; multitarget kinase inhibitor; osteosarcoma; patient derived xenograft; pediatric preclinical testing consortium; rhabdomyosarcoma.
© 2020 Wiley Periodicals, Inc.